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Abstract
Background: Arsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but
does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed
treatment benefits with manageable toxicity. Previously, we reported that metformin amplified the inhibitory effect
of ATO on intrahepatic cholangiocarcinoma (ICC) cells more significantly than other agents. Here, we investigated
the chemotherapeutic sensitization effect of metformin in ATO-based treatment in ICC in vitro and in vivo and
explored the underlying mechanisms.
Methods: ICC cell lines (CCLP-1, RBE, and HCCC-9810) were treated with metformin and/or ATO; the anti-
proliferation effect was evaluated by cell viability, cell apoptosis, cell cycle, and intracellular-reactive oxygen species
(ROS) assays. The in vivo efficacy was determined in nude mice with CCLP-1 xenografts. The active status of AMPK/
p38 MAPK and mTORC1 pathways was detected by western blot. In addition, an antibody array was used screening
more than 200 molecules clustered in 12 cancer-related pathways in CCLP-1 cells treated with metformin and/or
ATO. Methods of genetic modulation and pharmacology were further used to demonstrate the relationship of the
molecule. Seventy-three tumor samples from ICC patients were used to detect the expression of ERK3 by
immunohistochemistry. The correlation between ERK3 and the clinical information of ICC patients were further
analyzed.
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Results: Metformin and ATO synergistically inhibited proliferation of ICC cells by promoting cell apoptosis, inducing
G0/G1 cell cycle arrest, and increasing intracellular ROS. Combined treatment with metformin and ATO efficiently
reduced ICC growth in an ICC xenograft model. Mechanistically, the antibody array revealed that ERK3 exhibited the
highest variation in CCLP-1 cells after treatment with metformin and ATO. Results of western blot confirm that
metformin and ATO cooperated to inhibit mTORC1, activate AMP-activated protein kinase (AMPK), and upregulate
ERK3. Metformin abrogated the activation of p38 MAPK induced by ATO, and this activity was partially dependent
on AMPK activation. Inactivation of p38 MAPK by SB203580 or specific short interfering RNA (siRNA) promoted the
inactivation of mTORC1 in ICC cells treated with metformin and ATO. Activation of p38 MAPK may be responsible
for resistance to ATO in ICC. The relationship between p38 MAPK and ERK3 was not defined by our findings. Finally,
AMPK is a newfound positive regulator of ERK3. Overexpression of EKR3 in ICC cells inhibited cell proliferation
through inactivation of mTORC1. ERK3 expression is associated with a better prognosis in ICC patients.
Conclusions: Metformin sensitizes arsenic trioxide to suppress intrahepatic cholangiocarcinoma via the regulation
of AMPK/p38 MAPK-ERK3/mTORC1 pathways. ERK3 is a newfound potential prognostic predictor and a tumor
suppressor in ICC.
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Background
Cholangiocarcinoma is categorized as an intrahepa-
tic, perihilar, and distal cholangiocarcinoma that is
highly lethal [1]. Intrahepatic cholangiocarcinoma
(ICC) is the second most common type of primary
liver cancer [2], and in recent decades, the incidence
and mortality rates for this cancer have been in-
creasing worldwide. Although treatment approaches,
such as surgical resection, liver transplantation, systemic
chemotherapy, transarterial chemoembolization (TACE),
and radiofrequency ablation, were developed as therapeu-
tics for ICC, the prognosis of ICC patients is still very
poor. For advanced stage disease, systemic pharmaco-
therapy is usually the primary treatment. Cisplatin
plus gemcitabine is the first option for treatment of
patients with advanced biliary cancer, but this treat-
ment achieves a median overall survival of only
11.7 months [3].
Metformin, an anti-type II diabetes agent widely
used throughout the world, has been recognized as a
potentially preventive and therapeutic anticancer drug,
according to recent epidemiological surveys and la-
boratory studies. In 2013, an epidemiological study
that included 1828 potential ICC patients reported
that, in diabetic patients, metformin use was associ-
ated with a 60% reduction in ICC risk [4]. However,
in 2015, the same research group from the Mayo
Clinic analyzed 250 patients with cholangiocarcinoma
and observed that metformin could not improve the
survival of cholangiocarcinoma patients with diabetes
mellitus [5]. We previously reported that metformin
could inhibit the growth of ICC cells in vitro [6], and
another excellent study displayed similar results [7].
Moreover, we further found that metformin effectively
sensitized ICC cells to certain chemotherapeutic
agents, such as sorafenib, 5-fluorouracil, and arsenic
trioxide (ATO). Thus, as treatment with metformin
alone seems ineffective for ICC, combination of met-
formin with conventional chemotherapeutics may ele-
vate the therapeutic effect. For example, some recent
studies have revealed positive results using metformin
as chemosensitizer or radiosensitizer [8, 9].
ATO is a traditional Chinese medicine that is
mainly used to treat acute promyelocytic leukemia
(APL). For solid tumors, although numerous studies
have demonstrated the antitumor activity of ATO in
vitro and in vivo [10, 11], treatment with ATO alone
did not benefit patients [12]. Moreover, the required
doses of ATO increased the risk of side effects and
seriously limited further clinical use of ATO. Interest-
ingly, when combined with other agents or radiation,
ATO showed treatment benefits with manageable tox-
icity [12]. High dose and drug resistance might medi-
ate the failure of single ATO treatment in solid
tumor [12]. Accordingly, new strategies are needed to
enhance the antitumor activity of ATO or reverse the
drug resistance while reducing the required dose and
ATO-associated side effects.
In ICC cells, we found that metformin amplified the
inhibitory effect of ATO more significantly than other
agents. Our previous study reported that metformin
could enhance the antiproliferative effects of ATO in he-
patocellular carcinoma (HCC) cells [13]. In addition, nu-
merous studies have shown that the combination of
ATO with certain agents exhibited synergistic anticancer
effects against solid tumors [14–16]. Thus, we designed
this study to investigate the chemotherapeutic
sensitization effect of metformin in ATO-based treat-
ment in ICC in vitro and in vivo, and we further ex-
plored the underlying mechanism.
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Results
Metformin and ATO synergistically inhibited proliferation
of ICC cells by promoting cell apoptosis, inducing G0/G1
cell cycle arrest, and increasing intracellular ROS
The antiproliferative effects of combination treatment
with metformin and ATO were investigated in CCLP-1,
RBE, and HCCC-9810 cells using a system of real-time
cell growth monitoring with an RTCA DP Analyzer. As
shown in Fig. 1a, metformin (10 mM) in combination
with ATO (3 μM) nearly abrogated the growth of ICC
cells, according to the cell index. Moreover, to investi-
gate whether metformin plus ATO acts synergistically, a
median effect analysis [17] was performed, which
showed that the combination index (CI) value trended
toward values of less than one and then further de-
creased, as the combined antiproliferative effects in-
creased, indicating the combination was synergistic
(Fig. 1b). The concentrations of the two agents in each
group and the corresponding combined antiproliferative
effect values and Cis are listed in Additional file 1.
Next, we performed a cell cycle and apoptosis ana-
lysis. A significant increase in the number of cells
arrested in G0/G1 phase was observed in ICC cells
treated with a combination of metformin and ATO
compared to the single-drug treatments, as shown in
Fig. 1c, d. Similarly, the apoptosis assay, as shown in
Fig. 2a, revealed that a significant increase in the
number of apoptotic cells was observed in ICC cells
with a combination of metformin and ATO treatment,
compared to the single-drug treatment. Consistent
with the greater apoptotic events, the combined treat-
ment led to higher levels of cleaved PARP and
cleaved Caspase-3 and Caspase-3/7 activity in the
three ICC cell lines compared to the single-drug
treatment alone (Fig. 2c, d). As ATO can induce
mitochondrial-dependent ROS production in cancer
cells [18], we further determined the influence of
metformin on ATO-induced ROS production. As ex-
pected, the data in Fig. 2b shows that metformin
(10 mM) readily promoted ATO (3 μM)-induced ROS
production.
Collectively, these results revealed that combined
treatment with metformin and ATO remarkably pro-
motes antiproliferative effects by promoting cell apop-
tosis, inducing G0/G1 cell cycle arrest, and increasing
intracellular ROS.
Metformin and ATO regulate mTORC1, AMPK/MAPK, and
ERK3 in ICC cells in vitro
To analyze the potential molecular mechanism, we in-
vestigated the effects of metformin and ATO on the
mTORC1 and AMPK/MAPK pathways in ICC cells.
Metformin and ATO cooperated to abrogate the activa-
tion of mTORC1 (p-mTOR Ser2448, p-p70S6K Thr389,
p-Raptor Ser792, p-4E BP1 Thr37/46), as shown in
Fig. 3a, b. The inactivation effect of metformin (10 mM)
on mTORC1 seemed to be more profound than that of
ATO (3 μM). The consequences of combination treat-
ment with metformin and ATO on AMPK/MAPK net-
works were further investigated (Fig. 3c, d), revealing
that metformin and ATO could activate AMP-activated
protein kinase (AMPK) while the p-ERK (T202/204) reg-
ulated by metformin, and ATO was inconsistent in the
three cell lines used. However, activation of p38 MAPK
was observed in ATO-treated cells, and this activation
appeared to be almost completely abrogated by
metformin.
Moreover, to explore the molecular mechanism in de-
tail, we used a phospho-antibody array and screened
more than 200 molecules clustered in twelve cancer-
related pathways and found that total ERK3 exhibited
the highest variation in ICC cells after treatment with
metformin and ATO. The array data were quantified
and are listed in Additional file 2. ERK3, encoded by
MAPK6, is an atypical member of the MAPK family and
is, thus far, primarily believed to be an antitumor mol-
ecule [19, 20]. Although, recent studies have reported
that ERK3 can promote cancer cell migration and inva-
sion [21, 22]. Thus, to further define the role of EKR3 in
the metformin and ATO-induced antiproliferative effect
on ICC cells, we demonstrated the upregulation of ERK3
in ICC cells treated with both metformin and ATO using
a western blot assay (Fig. 3c, d). Phosphorylated ERK3
(detected by an anti-MAPK6 (phospho S189) antibody
from Abcam (ab 74032)) was detected, and no signifi-
cant variation was found when compared to total EKR3
(data not shown). Therefore, part of the following work
focused on the total ERK3 variation in the mechanism
studies.
Combined treatment with metformin and ATO efficiently
reduces ICC growth in an ICC xenograft model
To further validate our in vitro results showing the
antiproliferative effects of combined treatment with
metformin and ATO, we treated male athymic nude
mice bearing palpable tumors (approximately 100
mm3) of CCLP-1 xenografts with control (vehicle-
treated mice), metformin (200 mg/kg/day), ATO
(3 mg/kg/day), and a combination of metformin and
ATO (Figs. 4a–c) for 21 days. The tumor volumes of
the combination treatment group were significantly
reduced compared to the groups treated with either
metformin or ATO alone. To evaluate the safety, the
weights of the mice were obtained, and no significant
variation was found (Fig. 4d), implying that treatment
with a combination of metformin and ATO was very
safe. Consistent with the in vitro data, immunohisto-
chemistry and TUNEL analyses (Fig. 4e) of the
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xenograft tumors revealed that the metformin and
ATO combination effectively inhibited the expression
of Ki67, a marker representing tumor proliferation.
Moreover, metformin and ATO promoted apoptosis
in xenograft tumors, as evaluated by the cleaved
caspase-3 staining and TUNEL assay.
The combined treatment of metformin and ATO
suppressed the active status of mTORC1 and regulated
AMPK/p38 MAPK and ERK3 in ICC xenograft tumors,
consistent with the results in vitro
Similarly, xenograft tumors were further examined for
the status of mTORC1, AMPK/p38 MAPK, and ERK3
Fig. 1 Combination treatment with metformin and ATO synergistically suppresses proliferation in ICC cells in vitro. a After treatment with 10 mmol/L
metformin and 3 μmol/L ATO in combination or single treatments in ICC cells, the real-time cell growth was monitored for 72 h by using RTCA
Analyzer and the growth cures were shown. b ICC cells were treated with different concentrations of metformin and ATO for 48 h, CCK assay was used
evaluating the cell viability. The combination index was calculated as described in Methods. CI values less than one is considered synergism. c and d
After 48 h of treatment with 10 mmol/L metformin, 3 μmol/L ATO, or their combination, ICC cells were examined using PI staining and the cell cycle
distribution was measured by flow cytometric analysis. (Combination vs metformin or combination vs ATO *P < 0.05)
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after treatment with the control, metformin, ATO, or a
combination of both (Fig. 4f, g). Consistent with the in
vitro results, metformin, and ATO cooperated to inacti-
vate mTORC1, activate AMPK, and upregulate ERK3.
Moreover, activation of p38 MAPK was also observed in
mice in the ATO group, and this activation could be ab-
rogated by metformin (Fig. 4f, g). These results sup-
ported the findings of the molecular network in the
previous in vitro experiments.
AMPK and p38 MAPK-dependence of the antiproliferative
effect of metformin plus ATO on ICC cells
To characterize the mechanism responsible for
metformin-ATO synergism in ICC, we first thoroughly ex-
plored the roles of AMPK and p38 MAPK in the synergis-
tic effect. Accordingly, pharmacological and genetic
methods were used to regulate the expression level or ac-
tive status of AMPK and p38 MAPK. As shown in Fig. 5a,
b, and f, downregulation or inactivation of AMPK by short
Fig. 2 Metformin facilitates the pro-apoptotic effects of ATO on ICC cells through increasing the ROS production induced by ATO. a After treatment
with 10 mmol/L metformin, 3 μmol/L ATO, or a combination of both, ICC cells were examined using Annexin V/PI staining, and the distribution of
apoptotic cells was measured by flow cytometry. The percentages of early apoptotic cells plus late apoptotic/necrotic cells are shown in the bar graph.
b Cells were treated with 10 mmol/L metformin, 3 μmol/L ATO, or a combination of both for 24 h. The intracellular ROS were measured by flow
cytometric analysis using an oxidation-sensitive fluorescent probe, DCFH-DA, which is oxidized to DCF by ROS (the negative control was
not treated with DCFH-DA). The mean volumes of DCF are shown in the bar graph as the means ± SD from three independent experiments. c
Caspase3/7 activity in ICC cells treated with 10 mmol/L metformin, 3 μmol/L ATO, or a combination of both. d Cleaved caspase-3 and cleaved PARP
were monitored using western blot analysis. (Combination vs metformin or combination vs ATO *P < 0.05)
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interfering RNA (siRNA) or by compound C [23] rescued
the viability of ICC cells treated with the metformin and
ATO combination. An AMPK activator, AICAR, signifi-
cantly sensitized ICC cells to ATO (Fig. 5c), which further
demonstrated the AMPK-dependence of the antiprolifera-
tive effect of metformin plus ATO on ICC cells. Addition-
ally, similar methods were used for p38 MAPK, and the
results (Fig. 5d–f ) revealed that inactivation of p38 MAPK
by SB203580 [24] or specific siRNAs promoted the effect
of metformin and ATO on ICC cells, implying that
metformin-induced abrogation of activated p38 MAPK by
ATO may contribute to the metformin-ATO synergism in
ICC cells.
The role of ERK3 in the antiproliferative effect of
metformin plus ATO on ICC cells
As shown in Fig. 6a, b, downregulation of ERK3 by
MAPK6-specific siRNAs rescued the viability of ICC
cells treated with metformin and ATO, which implied
that ERK3 is a suppressive molecule in ICC cells.
The regulation network among AMPK, p38 MAPK, ERK3,
and mTORC1 in ICC cells
Inactivation of AMPK by compound C or specific
siRNA partially rescued metformin-induced inhibition
of p38 MAPK and partially abrogated metformin plus
ATO-induced upregulation of ERK3 and inhibition of
mTORC1 in ICC cells (Fig. 7a, c). This finding was
also supported by the molecular regulation observed
in cells treated with AICAR and ATO, shown in
Fig. 7b. For p38 MAPK, inactivation of p38 MAPK by
SB203580 or specific siRNA promoted the inactivation
of mTORC1 in ICC cells treated with metformin and
ATO (Fig. 7c); however, our results did not reveal the
relationship between p38 MAPK and ERK3. (Fig. 7a)
Moreover, downregulation of ERK3 by siRNA rescued
the active status of mTORC1 inhibited by the metfor-
min and ATO combination treatment (Fig. 7b), which
implied that ERK3 is a suppressor of mTORC1.
Collectively, we propose a potential molecular mech-
anism in which metformin and ATO inhibit ICC devel-
opment via modulation of a network involving the
AMPK, p38 MAPK, ERK3, and mTORC1 pathways
(Fig. 7e). Specifically, metformin and ATO cooperated to
inhibit mTORC1 through activation of AMPK and up-
regulation of ERK3. Meanwhile, metformin abrogated
the activation of p38 MAPK induced by ATO, which
partially depended on AMPK activation. The western
blot data of the three ICC cell lines are shown in
Additional file 3.
ERK3 functions as a suppressor in ICC development
The role of ERK3 in cancer is rarely explored. Therefore,
we further explored the function of ERK3 in ICC. We
found that overexpression of EKR3 in ICC cells inhibited
cell proliferation (Fig. 8a) through inactivation of
Fig. 3 The effects of metformin and ATO on the mTORC1 and AMPK/MAPK pathways in ICC in vitro. a and c The effect of metformin and ATO
single or combination treatment on the active status of mTORC1, AMPK/MAPK, and ERK3 pathways of ICC cells was determined by western
blotting. b and d The data were quantified and are represented as the means ± SD from three independent experiments. (Combination vs
metformin *P < 0.05, combination vs ATO #P < 0.05)
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mTORC1 (Fig. 8b). Overexpression of EKR3 also inhibited
the ICC xenograft growth (Fig. 8c). In addition, to explore
whether ERK3 could be a promising molecular marker for
predicting the prognosis of ICC patients, we detected the
expression level of ERK3 in tumor samples from 73 ICC
patients and compared the survival times of the patients
with the expression level (high or low) of ERK3 (Add-
itional file 4). As shown in Fig. 8d, high ERK3 expression
is associated with a better prognosis in ICC patients. In
addition, COX multivariate analysis showed that expres-
sion of ERK3 (low) and TMN stages (III and IV) are the
independent risk factors for shorter overall survival times
(Table 2 in Additional file 5). Collectively, these data im-
plied that ERK3 is a suppressor of ICC development.
Moreover, when correlated with clinical findings, we
found that the expression level of ERK3, segregated as
high or low, displayed a significant correlation with vessel
invasion, implying that ERK3 has an antiangiogenic effect
in ICC (Table 1 in Additional file 4), which is worth fur-
ther exploration in future studies.
Discussion
We demonstrated the synergistic interaction between
metformin and ATO in ICC cells. Metformin signifi-
cantly potentiates the effect of ATO against ICC in vitro
and in vivo. This interaction facilitates ROS production,
apoptosis, and cell cycle arrest. The PI3K-AKT-mTOR,
Ras-MAPK, JAK-STAT, and Notch pathways are the pri-
mary signaling networks in cholangiocarcinoma [1, 25].
The PI3K-AKT-mTOR and Ras-MAPK pathways have
profound effects on cell survival in cholangiocarcinoma
[25], and they have been identified as potential thera-
peutic targets in cancer treatment [26, 27]. However,
single-drug-based therapy strategies typically fail because
of the crosstalk between the PI3K-AKT-mTOR and Ras-
MAPK pathways [28, 29]. In the present study, we
evaluated the status of AMPK/mTORC1 and MAPK
underlying the synergistic antitumor effect of combined
metformin and ATO treatment in ICC cells.
As we described in our previous study [6], whether
activation of the mTOR pathway promotes the
Fig. 4 Metformin and ATO in combination potentiate the antiproliferative and pro-apoptotic effect of the single agent treatments in vivo through
mTORC1, AMPK/MAPK, and ERK3 pathways. a CCLP-1 cells were implanted subcutaneously into the flank regions of nude mice. When the tumor
volume reached approximately 100 mm3, vehicle (NS), metformin, ATO, or a combination of both were administered. (Combination vs metformin
or combination vs ATO *P < 0.05). After 3 weeks, the mice were euthanized, and the tumors are shown. b and c Tumor volume and tumor weight
were measured. d The weight of mice in each group was compared. e Representative hematoxylin-eosin (HE) stained images are shown, and the
expression of Ki67 and cleaved caspase-3 in the tumors was detected by IHC. In addition, apoptotic cells in the xenografted tumors were detected
by TUNEL assay. f The data were quantified and are presented as the means ± SD from three independent experiments. g The effect of metformin and
ATO single or combination treatment on the active status of mTORC1, AMPK/MAPK, and ERK3 in xenografts was determined by western blotting. The
data were quantified and are represented as the means ± SD. (Combination vs metformin *P < 0.05, combination vs ATO #P < 0.05)
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development of cholangiocarcinoma or predicts a
poor prognosis remains controversial. However,
mTORC1 has been demonstrated to be significant for
the growth of cholangiocarcinoma [30]. A prospective
pilot study reported that the mTORC1 inhibitor siro-
limus can induce temporary partial remission or
stabilization of cholangiocarcinoma [31]. Thus, we de-
duced that a combination of metformin and ATO
would synergistically abrogate the activation of
mTORC1 in ICC in vitro and in vivo, which may be
partially be responsible for the synergistic anticancer
effect of the two agents. The p38 MAPK pathway is a
promising target of ATO. ATO activated p38 MAPK
and subsequently inhibited the Akt/mTOR signaling
pathways to suppress tumor cell growth [32, 33].
Conversely, p38 MAPK may promote tumorigenesis
and development in cholangiocarcinoma [34, 35].
Thus, we evaluated the role of ATO-triggered activa-
tion of p38 MAPK in growth suppression of cholan-
giocarcinoma. Our results suggested that inactivation
of p38 MAPK by the p38 MAPK inhibitor SB203580
or p38 MAPK-specific siRNA could enhance the anti-
cancer effect of single agent or combined metformin
and ATO treatment, especially the ATO single-drug
treatment. Thus, activation of p38 MAPK may be re-
sponsible for resistance to ATO in cholangiocarci-
noma. These results are consistent with some other
finding regarding the MAPK-induced resistance of
cancer cells to ATO [36]. Metformin significantly
inhibited the ATO-induced activation of p38 MAPK
in ICC cells in vitro and in vivo, which may also
mechanistically explain the synergistic anticancer ef-
fect of the two agents.
ERK3, encoded by MAPK6, is an atypical member of
the MAPK family, which can suppress cell proliferation
via the ERK3-MAPK-activated protein kinase-5(MK5)
pathway [19]. In our study, metformin and ATO in-
creased the expression of ERK3 via activation of AMPK.
ERK3 partially bridged the inactivation of mTORC1 in-
duced by metformin and ATO in ICC cells. Moreover,
Fig. 5 The role of AMPK and p38 MAPK in the antiproliferative effect of metformin and ATO combination treatment on ICC cells. a
Downregulation of AMPK by specific siRNAs partially rescued ICC cell survival in cells treated with metformin and ATO. b Inactivation of AMPK by
compound C partially rescued ICC cell survival in cells treated with metformin and ATO (*P < 0.05). c The activator of AMPK, AICAR, potentiated
the antiproliferative effect of ATO on ICC cells. (Combination vs AICAR *P < 0.05, combination vs ATO #P < 0.05). d and e Downregulation of p38
MAPK by specific siRNAs or inactivation of p38 MAPK by SB203580 potentiated the antiproliferative effect of metformin and ATO combination
treatment on ICC cells. f The expression level of AMPK and p38 MAPK was detected by western blot in ICC cells after specific siRNA interference
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we are the first to report that increased expression of
ERK3 inhibited ICC cell growth in vitro and in vivo, and
high ERK3 expression in tumor samples predicted a bet-
ter prognosis in ICC patients after tumor resection.
Therefore, ERK3 may be a protective molecule in ICC
progression. The functions of ERK3 are poorly under-
stood. MK5 is a recognized downstream target of ERK3,
which can phosphorylate MK5 on Thr-182 [19]. The
phosphorylation activity of MK5 may be responsible for
energy depletion-induced suppression of mTORC1 [37].
In the present study, we demonstrated that ERK3 is a
suppressor of mTORC1, which we speculate may be me-
diated by activation of MK5. For future studies, we
should further investigate the role of the ERK3-MK5-
mTORC1 pathway in the antitumor effect of combined
metformin and ATO treatment in ICC cells, which may
be the primary deficiency of our study. p38 MAPK is an-
other potential activator of MK5 [37, 38]. Our results
did not suggest that regulation between p38 MAPK and
ERK3 occurs. However, as we described previously, in-
activation of p38 MAPK mechanistically bridged the
synergistic anticancer effect of metformin and ATO.
Therefore, the p38 MAPK-MK5 pathway is also worth
exploring in detail. Furthermore, investigation of the in-
fluence of ERK3 on biological activity, such as apoptosis
and drug sensitivity in ICC cells, is needed.
In regard to the regulation of p38 MAPK and ERK3,
few studies have reported an AMPK-dependent effect.
As a significant target of metformin, AMPK bridged the
primary activity of metformin [23]. Activation of AMPK
by metformin or AICAR activated p38 MAPK and in-
creased the expression of ERK3. Nevertheless, we did
not find that the activation of p38 MAPK by ATO was
influenced by modulation of AMPK, which may be ex-
plained by the fact that direct activation of p38 MAPK
by ATO overcomes the inhibitory effect of ATO-
triggered AMPK activation. Moreover, for EKR3, AMPK
is a newfound positive regulator, although more mecha-
nisms are likely to be involved in metformin and ATO-
triggered increased expression of ERK3.
Conclusions
Metformin potentiates the effect of arsenic trioxide sup-
pressing ICC cells in vitro and in vivo. Because metfor-
min or ATO alone does not seem to be beneficial for
ICC patients or patients with certain other solid tumors,
treatment of ICC patients with a combination of metfor-
min and ATO-based chemotherapy could be considered
in a clinical setting. Mechanistically, we demonstrated
that metformin and ATO targeted both the PI3K-AKT-
mTOR and Ras-MAPK pathways, the crosstalk of which
is disrupted by metformin and ATO through AMPK/p38
MAPK-ERK3/mTORC1 pathway. ERK3 is a newfound
molecular marker for predicting the prognosis of ICC
patients after resection, and the function of ERK3 in
ICC needs to be investigated in future studies. Detection
of the p38 MAPK activation status and the expression of
ERK3 are valuable for evaluating the sensitivity of ICC
to metformin and ATO.
Methods
Cell culture
Three ICC cell lines, CCLP-1 [39], RBE, and HCCC-
9810, were used. The CCLP-1 cell line was obtained
from DSMZ (Braunschweig, Germany). RBE and
HCCC-9810 cells were purchased from the Type
Fig. 6 Downregulation of ERK3 rescues ICC cell survival in cells treated with both metformin and ATO. a Downregulation of AMPK by specific
siRNAs partially rescued ICC cell survival in cells treated with metformin and ATO (*P < 0.05). b The expression level of ERK3 was detected by
western blot in ICC cells after MAPK6-specific siRNA interference
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Culture Collection of the Chinese Academy of Sci-
ences (Shanghai, China). CCLP-1 cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM)-high
glucose (Gibco, USA). RBE and HCCC-9810 cells
were cultured in RPMI-1640 (Gibco, USA) supple-
mented with 10% fetal bovine serum (FBS; Gibco)
and 100 μg/ml each of penicillin and streptomycin




boxamide 1-β-D-ribofuranoside Acadesine N1-(β-D-
Ribofuranosyl)-5-aminoimidazole-4-carboxamide, A9978)
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Compound C (Dorsomorphin, 6-[4-(2-Piperidin-1-
ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine,
P5499) and SB239063 (trans-1-(4-Hydroxycyclohexyl)-4-
(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole,
S7741) were purchased from Selleck Chemicals (Houston,
TX, USA). Arsenic trioxide (As2O3, ATO) was purchased
from Shuanglu Pharmaceutical Co., Ltd. (Beijing, China).
The cell counting kit-8 (CCK-8, KGA317), the Annexin
V-FITC Apoptosis Detection Kit (KGA108), the cell cycle
detection kit (KGA512), Caspase3/7 Activity Detection
Kit (KGAS037), the terminal deoxynucleotidyltransferase-
Fig. 7 The role of AMPK, p38 MAPK, and ERK3 in metformin and ATO-induced mTORC1 inhibition in ICC cells. a The expression level of p-p38
MAPK/p38 MAPK and ERK3 was detected by western blot in ICC cells that were treated with metformin and ATO and in which AMPK or p-p38
MAPK was inhibited by siRNA or inhibitors (*P < 0.05). b The activation status of AMPK, p38 MAPK, ERK3, and mTORC1 was detected by western
blot in ICC cells treated with AICAR and ATO. (Combination vs AICAR *P < 0.05, combination vs ATO #P < 0.05). c The activation status of mTORC1
was detected by western blot in ICC cells that were treated with metformin and ATO and in which AMPK or p-p38 MAPK was inhibited by siRNA
or inhibitors (*P < 0.05). d The activation status of mTORC1 was detected by western blot in ICC cells treated with metformin and ATO and MAPK6-
specific siRNA to downregulate ERK3 (*P < 0.05). e The proposed relationship between AMPK, p38 MAPK, and ERK3 in response to metformin- and
ATO-induced mTORC1 inhibition in ICC cells. The green lines indicate the inhibition of mTORC1 by metformin and ATO. The red lines indicate the
activation of mTORC1 by ATO
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mediated deoxyuridine triphosphate (dUTP) nick-end la-
beling (TUNEL) Assay Kit (KGA707), and the ROS (react-
ive oxygen species) Detection Kit (KGT010) were
purchased from KeyGen Biotech (Nanjing, China). The
HistostainTM-Plus Kits (IgG/Bio, S-A/HRP, DAB) were
purchased from Zhongshan Golden Bridge Co., Ltd.
(Beijing, China).
Antibodies
The following antibodies were used for immunoblot-
ting or immunohistochemical staining: β-actin (sc-
47778) was from Santa Cruz Biotechnology, Inc. Sant
(Santa Cruz, CA, USA). AMPKα (#2532) and phos-
phorylated AMPKα (Phospho-Thr172, #2535), mTOR
(#2983), phosphorylated mTOR (Phospho-Ser2448,
#5536), phosphorylated Raptor (Phospho-Ser792,
#2083), phosphorylated p70 S6 kinase (Phospho-
Thr389, #9234), phosphorylated 4E-BP1(Phospho-
Thr37/46, #2855), cleaved PARP (#5626), cleaved
caspase-3(#9661), ERK (#4696), phosphorylated
ERK(Phospho-Thr202/Tyr204, #4370), p38 MAPK(#8690),
phosphorylated p38 MAPK(Thr180/Tyr182, #4511), and
Ki-67 (#9449) were from Cell Signaling Technology, Inc.
(Danvers, MA, USA). ERK3(ab53277) was from Abcam
(Cambridge, MA, USA). Goat anti-rabbit and goat anti-
mouse IgG peroxidase-conjugated secondary antibodies
(31460 and 31430) were from Thermo-Pierce
(Rockford, IL, USA).
Real-time cell growth monitoring
The real-time cell growth was monitored using a 16
× E-Plates RTCA DP Analyzer (ACEA Biosciences).
After 5000 cells were seeded in a well of 16 × E-
Plates for 16 to 24 h, the medium was replaced by
fresh medium with certain agents (control, metformin
(10 mmol/L), ATO (3 μmol/L) or a combination of
both). Then, the cell index, representing the cell via-
bility, was detected every 15 min for 72 h. Four repli-
cates were prepared for each condition. The growth
cures are shown.
Fig. 8 The biological and molecular roles of ERK3 in ICC. a ICC cells with lentiviral vector-mediated transfer of MAPK6 or GFP were assessed using a
CCK-8 assay to evaluate the cell proliferation variation (*P < 0.05). (b) The mTORC1 status in ICC cells with lentiviral vector-mediated transfer of
MAPK6 or GFP was detected by western blot. c CCLP-1 cells with lentiviral vector-mediated transfer of MAPK6 or GFP were implanted
subcutaneously into the flank regions of nude mice. After 4 weeks, the mice were euthanized, and the tumors are shown. The expression
of ERK3 in the xenografts was detected by IHC. d ERK3 was detected by IHC in tumors from 73 ICC patients after surgery. The relevance
of the ERK3 expression level and the prognosis of ICC patients was evaluated by the Kaplan-Meier method
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Cell viability assay
Cell viability was determined using a CCK-8 assay ac-
cording to the manufacturer’s instructions. The detailed
procedure has been described previously [6].
Determination of synergism
The synergism of metformin and ATO was determined
using the method of Chou [17] and the software package
Calcusyn (Biosoft, Cambridge, United Kingdom). Com-
bination indices (CI) were calculated, and a CI less than
1 was defined as synergism.
Cell cycle, apoptosis, and ROS evaluation
The cell cycle arrest, induction of apoptosis, and intra-
cellular ROS levels were determined by flow cytometry.
Portions of the detailed procedure have been described
previously [6].
For the detection of intracellular ROS, an oxidation-
sensitive fluorescent probe (DCFH-DA) was used. After
treatment with agents for 24 h, a total of 1 × 106 cells
were trypsinized and pelleted by centrifugation and
washed twice with PBS. Then, the cell pellets were re-
suspended in 1 mL of DMEM or RPMI-1640 (serum-
free) with 10 μm/L DCFH-DA and incubated for 20 min
at 37 °C. The stained cells were analyzed using a flow
cytometer (Accuri Cytometers Inc.). The FL1-A received
the fluorescence induced by DCF. For each sample, 10,
000 events were collected.
A Caspase3/7 activity detection kit was used according
to the manufacturer’s instructions. Briefly, after treat-
ment with agents for 48 h, 1 × 106 cells were incubated
in 1 μm/L working solution for 30 min at 37 °C. Finally,
the optical density was measured using a microplate
reader (Thermo, Varioskan Flash).
Phospho-antibody array
Phosphoprotein profiling by the cancer-signaling
phospho-antibody microarray—the cancer-signaling
phospho-antibody microarray PCS248, which was de-
signed and manufactured by Full Moon Biosystems, Inc.
(Sunnyvale, CA), contains 248 antibodies. Each of the
antibodies has six replicates that are printed on coated
glass microscope slides, along with multiple positive and
negative controls. The antibody array experiment was
performed by Wayen Biotechnology (Shanghai, China),
according to their established protocol. Briefly, cell ly-
sates obtained from CCLP-1 cells treated with single or
double agents were biotinylated with an Antibody Array
Assay Kit (Full Moon Biosystems, Inc.). The antibody
microarray slides were first blocked in a blocking solu-
tion (Full Moon Biosystems, Inc.) for 30 min at room
temperature, rinsed with Milli-Q grade water for 3–
5 min, and dried with compressed nitrogen. The slides
were then incubated with the biotin-labeled cell lysates
(~100 μg of protein) in coupling solution (Full Moon
Biosystems, Inc.) at room temperature for 2 h. The array
slides were washed 4–5 times with 1X Wash Solution
(Full Moon Biosystems, Inc.) and rinsed extensively with
Milli-Q grade water before detection of bound biotinyl-
ated proteins using Cy3-conjugated streptavidin. The
slides were scanned on a GenePix 4000 scanner, and the
images were analyzed with GenePix Pro 6.0 (Molecular
Devices, Sunnyvale, CA). The fluorescence signal (I) of
each antibody was obtained from the fluorescence inten-
sity of antibody-stained regions. A ratio computation
was used to measure the extent of protein phosphoryl-
ation. The phosphorylation ratio was calculated as
follows: phosphorylation ratio = phospho value/non-
phospho value. The total proteome ratios were standard-
ized by β-actin.
Western blot analysis
Cells after different treatments or tumor tissues from a
xenograft were harvested for western blot analysis. The
detailed procedure has been described previously [6].
Primary antibodies (described in the Antibodies section)
were incubated at 4 °C overnight. The bands were visu-
alized by chemiluminescence, imaged using a ChemiDoc
XRS and analyzed using Image Lab (both from Bio-Rad).
Xenograft model analysis
To investigate the antiproliferative effect of metformin
and ATO in combination treatment on ICC cells in vivo, a
model of nude mice bearing ICC cell xenografts was
established. Five-week-old male athymic nude mice were
obtained from the Animal Facility of Zhejiang University.
The mice were maintained under pathogen-free condi-
tions and were provided with sterilized food and water.
Briefly, 5 × 106 CCLP-1 cells were injected subcutaneously
into the right flank of each nude mouse. When mice ex-
hibited palpable tumors (the tumor volume was approxi-
mately 100 mm3), they were randomly divided into
control (100 μL of NS by intraperitoneal injection), met-
formin (150 mg/kg/day diluted in 100 μL of NS by intra-
peritoneal injection), ATO (2.5 mg/kg/day diluted in
100 μL of NS by intragastric administration), and a com-
bination of both (metformin, 150 mg/kg/day plus ATO
3 mg/kg/day diluted in 100 μL of NS by intraperitoneal in-
jection) groups (n = 6 animals per group). The treatments
were performed five times per week for 3 weeks. The
tumor volume was detected every week and was calcu-
lated using the following formula: volume = 1/2 (length ×
width2). After 4 weeks, all the mice were sacrificed, and
the tumors were isolated. NS means normal saline.
To evaluate the antiproliferative effect of ERK3 in ICC
in vivo, 5 × 106 CCLP-1 cells with ERK3 overexpression
or GFP transfection were injected subcutaneously into
the right flank of each nude mouse. After 4 weeks, the
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tumor volume was determined and calculated, as previ-
ously described, all the mice were sacrificed, and the tu-
mors were isolated.
Immunohistochemical staining and evaluation
The tumors isolated from the mice were paraffin embed-
ded and cut into 10-μm-thick sections in a microtome
cryostat (HM500 OM, Carl Zeiss, Germany). Immuno-
histochemical staining was conducted according to the
manufacturer protocols described for HistostainTM-Plus
Kits. Primary antibodies (described in the Antibodies
section) were incubated at 4 °C overnight. Images were
captured with a light microscope (Axiolab, Carl Zeiss,
Germany), and five images/sample were prepared.
Image-Pro Plus 4.5 Software was used to analyze the
staining data.
ERK3 expression in the 73 cases was evaluated by two
of the authors (Hai-Yang Xie and Fan Yang), who were
blind to the clinicopathological data. Any discrepancy
between the two individuals was resolved by a third indi-
vidual. A semiquantitative scoring system was used.
Brown granules in the cytoplasm representing ERK3
were considered positive staining. We scored the stain-
ing intensity as follows: 0, no staining; 1+, mild staining;
2+, moderate staining; 3+, intense staining. The area of
staining was evaluated as follows: 0, no staining of cells
in any microscopic field; 1+, <30% of tissue stained posi-
tive; 2+, between 30 and 60% of tissue stained positive;
and 3+, >60% of tissue stained positive. ERK3 expression
was evaluated by combining the staining intensity and
area assessments. The minimum score when summed
(intensity + extension) was 0, and the maximum score
was 6. Scores ≤3 were defined as low expression, and
scores >3 were defined as high expression.
TUNEL assay
In situ detection of apoptotic cells in the tumors isolated
from the mice was performed with a TUNEL assay. The
tumors were paraffin embedded and cut into 10-μm-
thick sections in a microtome cryostat (HM500 OM,
Carl Zeiss, Germany). The TUNEL assay was conducted
according to the manufacturer’s protocols. 3,3-Di- ami-
nobenzidine (DAB) was used as the substrate for the
peroxidase. Images were captured with a light micro-
scope (Axiolab, Carl Zeiss, Germany), and five images/
sample were prepared. Image-Pro Plus 4.5 Software was
used to analyze the staining data.
Gene knock-down using siRNA
ICC cells were seeded in a 6-well plate at a concentra-
tion of 2 × 105 cells per 2 ml in medium with FBS, peni-
cillin, and streptomycin. After 24 h, the medium was
replaced with fresh medium without antibiotics or FBS.
Meanwhile, siRNA or a negative control oligonucleotide
was transfected into the cells with Lipofectamine 3000,
according to the manufacturer’s instructions. After 24 h,
the medium was replaced with fresh complete medium.
Then, the cells were cultured for subsequent experi-
ments. All siRNAs were obtained from Shanghai
GenePharma Co., Ltd. China; the sequences of siRNAs
are listed in Additional file 6.
Stable overexpression of ERK3 (encoded by MAPK6) in
ICC cells
Lentiviral particles containing MAPK6 vector or empty
vector were obtained from Shandong Vigenebio Co.,
Ltd. (Jinan, China). Cells were plated in a six-well plate
at 2 × 105 cells/well in supplemented medium 24 h be-
fore viral infection. Media were removed from well
plates and replaced with media supplemented with Poly-
brene at a final concentration of 5 μg/ml. Next, cells
were infected by adding lentiviral particles to the culture.
Stable clones expressing MAPK6 or GFP were selected
using puromycin dihydrochloride. Then, cells were col-
lected for gene expression assays.
Patient samples
Tumor samples from a total of 73 ICC patients who
underwent operations at our hospital (First Affiliated
Hospital, Zhejiang University School of Medicine,
Zhejiang, China) between 2010 and 2014 were used in
the present study. These patients were diagnosed with
ICC either before or after surgery. No treatment was
done for the patients before surgery. The diagnosis was
confirmed by histopathological examination, and
complete clinical and laboratory data were collected be-
fore surgery and during follow-up. The distribution of
clinicopathological data in the study cohort is given in
Table 1 of Additional file 4. Specimens of cancer tissues
and clinical information were available from these pa-
tients after obtaining informed consent.
Statistical analysis
SPSS 21.0 statistical software was used for the statistical
analysis. Values are presented as the mean ± SD. Statis-
tical analyses were performed using Student’s t-test. The
analysis of multiple groups was performed by ANOVA
with an appropriate post hoc test.
Additional files
Additional file 1: The concentrations of metformin(Met) and arsenic
trioxide(ATO) in each group and its corresponding combined
antiproliferative effect values and CI. (DOCX 14 kb)
Additional file 2: Proteome and phosphoproteome array data. (TIF 966 kb)
Additional file 3: The western blot data of the three ICC cell lines.
(TIF 9809 kb)
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Additional file 4: Clinicopathological correlation of ERK3 expression in
73 ICC patients. (DOCX 14 kb)
Additional file 5: Univariate and multivariate survival analyses of
potential predictors of overall survival in ICC patients following operation.
(DOCX 17 kb)
Additional file 6: The sequences of siRNAs used in this study. (DOCX 36 kb)
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